The research and development of a 5-HT selective reuptake blocker. Preclinical aspects.
The preclinical development of zimeldine according to the 5-HT (serotonin) hypothesis is briefly reviewed. Zimeldine is a selective 5-HT reuptake inhibitor based on the "chemical lead" of brompheniramine--an antihistamine with some 5-HT reuptake inhibitory properties. By chemical manipulation of the position of the pyridine ring in brompheniramine and the stereochemistry of the side chain, a selective 5-HT reuptake inhibitor has been developed.
D000818:Animals; D002626:Chemistry, Pharmaceutical; D004353:Drug Evaluation, Preclinical; D006801:Humans; D019964:Mood Disorders / Q000503:physiopathology; D009638:Norepinephrine / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D013569:Synapses / Q000502:physiology; D015031:Zimeldine / Q000494:pharmacology*
D012701:Serotonin; D015031:Zimeldine; D009638:Norepinephrine